Akihiko Ozaki, M.D., Ph.D. Physician at the Medical Governance Research Institute In recent years, the breast cancer field, which the author is responsible for, has seen a continuous succession of new drug developments. In 2024, capivasertib ("Truqap") for hormone receptor-positive breast cancer with specific gene mutations (PIK3CA, AKT1, PTEN) was approved in March, sacituzumab govitecan ("Trodelvy") for triple-negative breast cancer in November, and datopotamab deruxtecan (